Clinical Trial Update: AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AMG 706 (motesanib) with octreotide in low-grade neuroendocrine tumors has completed enrollment and results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Carcinoid Tumor
• Islet Cell Tumor

Drugs mentioned

• AMG 706 (motesanib)
• OCTREOTIDE (OCTREOTIDE ACETATE)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Status: COMPLETED | Results posted: 2015-06-04